ESR1 and breast cancer: Findings by the monarchE committee [9] have demonstrated benefits of adding a cyclin-dependent kinase 4/6 inhibitor (abemaciclib) to hormone therapy in early-stage ER-positive (ER+) HER2-negative (HER2–) BC patients with lymph node involvement.